Wegovy celebrates first birthday with subdued cheers
Novo Nordisk’s obesity drug Wegovy has had an eventful year. After getting off to a flying start, the firm hit a wall soon after launching when it became evident that demand far exceeded production capacity. Still, there’s light at the end of the tunnel, say two analysts.
by christopher due karlsson, translated by daniel pedersen
Almost exactly one year ago, on June 4, Denmark’s biggest pharmaceutical firm, Novo Nordisk, was granted approval by the US Food and Drug Administration (FDA) for the firm’s obesity drug, Wegovy.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves Eli Lilly diabetes drug
For subscribers
Launch of obesity drug will be Novo Nordisk's fastest ever
For subscribers
.jpg&w=384&q=75)
